BCAX - Bicara Therapeutics Inc. News

BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target

BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

defenseworld.net

Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX

Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9%

Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and

Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform

Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweigh

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp a

Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and ra

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targe

Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-W

BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39

BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises th

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Q2 Earnings Call Highlights

Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership ch

Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the anal

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 1

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage

fool.com

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on

Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negat

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clini

Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembro

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep

At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembroliz

fool.com

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for onco

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on tr

Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transc

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage b

Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and

Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweigh

Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42

Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy

Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript

Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics NASDAQ: BCAX said it made progress during the first quarter of 2026 on the devel

Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the an

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-wee

Earnings Scheduled For May 11, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16

Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and

Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target

Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform

Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-W

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW c

Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target

Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outp

HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Raises Price Target to $42

HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a B

Bicara Therapeutics Q4 EPS $(0.68), Inline

Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analy

Earnings Scheduled For March 30, 2026

Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Ea

Bicara Therapeutics Inc (BCAX) to release Q4 earnings on March 30. Expected loss of 65 cents/share.

B of A Securities Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target

B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) wi

Bicara Therapeutics Data From Phase 1b Expansion Cohort Of 2000mg Of Ficerafusp Alfa Every Other Wee

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bri

Citizens Initiates Coverage On Bicara Therapeutics with Market Outperform Rating, Announces Price Ta

Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a